Repligen completes BioLife Solutions acquisition
BioLife stockholders received $11.25 per share in cash plus 0.1442 Repligen shares for each share they held
Published
Chart: RGEN, one-minute prices, three sessions
Repligen has closed its acquisition of BioLife Solutions, effective October 6, 2026. BioLife, which makes cell processing tools for the cell and gene therapy market, now operates as a wholly owned subsidiary, and its stock has been removed from Nasdaq.
Repligen CEO Olivier Loeillot said the acquisition "expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue."
The closing removes the uncertainty that typically weighs on an acquirer's shares while a cash-and-stock deal is still pending, shifting attention to how Repligen executes. BioLife's consumables business, tied to cell and gene therapy manufacturing, now sits fully inside Repligen's operations rather than standing as a separate target with its own disclosures. Repligen said it will detail the transaction's expected impact on its 2026 financial outlook on its upcoming third quarter earnings call, which will be the first real test of whether the promised margin and growth benefits show up in guidance rather than just in the rationale for the deal.